Donald Bostic
Medical · Austin, INNPI 1437347929
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,211 of the $18,373 with a category attached, or 71.9%. Novo Nordisk accounts for 84.6% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $9,268 and has fallen 90.1% since, to $917 in 2024. Among medical clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $83.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$16K
- AbbVie$442
- Bayer$431
- Boehringer Ingelheim$347
- Lilly USA, LLC$179
- Nestle Healthcare Nutrition Inc.$143
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$13,21172%
- Travel & lodging$1,2997%
- Food & beverage$3,86421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,373 in reported general payments places this provider in the 95th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 197 | $243,399 |
| MounjaroTirzepatide | 157 | $172,042 |
| JardianceEmpagliflozin | 144 | $144,265 |
| RybelsusSemaglutide | 66 | $105,321 |
| TradjentaLinagliptin | 129 | $93,548 |
| KerendiaFinerenone | 99 | $86,398 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $73,049 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 64 | $52,230 |
| FarxigaDapagliflozin Propanediol | 50 | $51,415 |
| LinzessLinaclotide | 35 | $43,764 |
| Nurtec OdtRimegepant Sulfate | 20 | $38,418 |
| TrulicityDulaglutide | 23 | $33,823 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $31,117 |
| VascepaIcosapent Ethyl | 36 | $20,646 |
| VraylarCariprazine Hcl | 14 | $19,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $15,544 | $356,803277 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat, Glyxambi | $347 | $326,982389 claims |
| Lilly USA, LLCMounjaro, Trulicity | $179 | $205,865180 claims |
| BayerKerendia | $431 | $86,39899 claims |
| AbbVieLinzess, Vraylar | $442 | $63,68349 claims |
| PfizerNurtec Odt, Eliquis | $55 | $51,56039 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $113 | $7,20320 claims |
| MerckJanuvia | $22 | $6,75612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $1,829198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 273 medical providers in Indiana.
Other medical in Austin
- Meggie BeckleyIndianapolis$125K
- Jennifer ConnerIndianapolis$98K
- Brandon BoydCarmel$46K
- Karey DavisNew Castle$45K
- Sheryl NewCarmel$39K
- Lindsey GradyValparaiso$39K
- Jennifer IrwinIndianapolis$34K
- Dennae DaltonZionsville$33K
- Jenifer FortneyFort Wayne$26K
- Jordan Stemer-MirandaCrown Point$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.